DOD cancer research programs face 57% funding cut in year-long continuing resolution Pancreatic, lung, kidney cancer research programs eliminated

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Our Hispanic community is a vibrant and essential part of the American tapestry, contributing richly to the country’s society, culture, and economy. Yet, when it comes to healthcare, this community grapples with significant disparities, especially in cancer care.

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

June 06, 2025

Vol.51 No.22

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

Patients with colon cancer who consumed an anti-inflammatory diet during a phase III clinical trial showed longer overall survival post-treatment, compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.

June 06, 2025

Vol.51 No.22

DOD cancer research programs face 57% funding cut in year-long continuing resolution

Pancreatic, lung, kidney cancer research programs eliminated

YOU MAY BE INTERESTED IN

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Renew today!

Subscriber content

Never miss an issue!

Login